Meds A-Z
Cefpodoxime
Detailed information about Cefpodoxime
Pet Owner Quick Guide
Start here: what this medicine is for, what it does, and when it's usually needed.
Usually used for:
For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , S. aureus , Streptococcus canis (group G, beta-hemolytic), Escherichia coli , Pasteurella mul...
What it does:
For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , Staphylococcus aureus , Streptococcus canis (group G, ß hemolytic), Escherichia coli , Pasteu...
When it's needed:
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian
Call your vet sooner if you notice:
- Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian
Commonly reported reactions:
- (2 reports)
- (2 reports)
- (1 reports)
What to ask your vet today:
- Is this medicine the right fit for my pet’s current symptoms?
- Which warning signs mean I should call back right away?
- How should I handle missed doses or refusal to take the medicine?
Cefpodoxime
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Both
Manufacturer: MSK
Quick Facts
Official label facts first, then secondary summaries. Marketing content is separated below.
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200815 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200543 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source
Warnings / Contraindications
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian
- High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source
Adverse Reactions
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Tap or hover a reaction to see what it means in plain language.
Most Reported Reactions
| Reaction | Cases | Species | Serious cases |
|---|---|---|---|
| 2 | Cat, Dog | 2 | |
| 2 | Cat, Dog | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 | |
| 1 | Dog | 1 | |
| 1 | Cat | 1 |
Species coverage: Cat (20) Dog (12)
View detailed reaction table
| Reaction | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 |
- https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-013835
Storage & Handling
No storage/handling guidance is linked yet.
Documents
Official label facts are separated from secondary summaries.
Official documents: 7 • Secondary summaries: 0
- FOI Summary oA 200-815 Approved July 8, 2025.pdf · FOI
- Cefpodoxime Proxetil Tablets · SPL
- UCM338192.pdf · FOI
- Cefpodoxime Proxetil Tablets · SPL
- UCM433791.pdf · FOI
- ucm118043.pdf · FOI
- Simplicef® · SPL
No source yet.
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17208 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/17507/Cefpodoxime%20Proxetil%20Tablets · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/1230 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2217/Cefpodoxime%20Proxetil%20Tablets · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/772 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/771 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/269/Simplicef%C2%AE · document · SPL
Promotional Materials (Marketing)
This content is marketing material and not clinical guidance.
No marketing assets are linked yet.
No source yet.
Technical appendix (vet reference)
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
At a Glance
Quick facts and links to official labeling and safety signals.
- Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
-
Animal Drugs @ FDA:
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Applications/products are imported from FDA export data.
-
Animal Drugs @ FDA previews:
Source FDA
| Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
-
Animal Drug Product Listing Directory (NDC):
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
- openFDA reaction terms: Source FDA openFDA | Refreshed Feb 16, 2026, 11:04 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:22 AM UTC
Diagnosis-code mappings are not available for this medication yet.
Counseling and Monitoring Highlights
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
- Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian (Contraindication, High)
Identifiers & Packages
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 11695-7040-1 | 11695 | - | |
| 11695-7040-2 | 11695 | - | |
| 11695-7041-1 | 11695 | - | |
| 11695-7041-2 | 11695 | - | |
| 17033-431-10 | 17033 | - | |
| 17033-432-10 | 17033 | - | |
| 54771-5228-1 | 54771 | - | |
| 54771-5228-2 | 54771 | - | |
| 54771-5229-1 | 54771 | - | |
| 54771-5229-2 | 54771 | - | |
| 73309-025-01 | 73309 | - | |
| 73309-025-02 | 73309 | - | |
| 73309-025-03 | 73309 | - | |
| 73377-069-01 | 73377 | - | |
| 73377-069-02 | 73377 | - | |
| 73377-069-03 | 73377 | - | |
| 86101-033-71 | 86101 | - | |
| 86101-033-76 | 86101 | - | |
| 86101-034-71 | 86101 | - | |
| 86101-034-76 | 86101 | - |
Enriched Documents
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
-
FOI Summary oA 200-815 Approved July 8, 2025.pdf
• FOI summary • Official
• July 31, 2025
FDA FOI summary for application 200815
-
UCM338192.pdf
• FOI summary • Official
• March 16, 2019
FDA FOI summary for application 200543
-
ucm118043.pdf
• FOI summary • Official
• March 15, 2019
FDA FOI summary for application 141232
-
UCM433791.pdf
• FOI summary • Official
• March 15, 2019
FDA FOI summary for application 141232
Data Sources & Revision History
Every non-trivial field is expected to include provenance and update timestamps.
- contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Official, 2026-02-12)
- side_effects: Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, Lethargy (see also Central nervous system depression in 'Neurological'), Diarrhoea, Letharg… (Official, 2026-02-12)
- usage: For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , Staphylococcus aureus , Streptoc… (Official, 2026-02-12)
- side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
FDA Products & Applications (Animal Drugs @ FDA)
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
Cefpodoxime Proxetil Tablets
RX
Cefpodoxime proxetil
Tablet
• Oral
|
Felix Pharmaceuticals Pvt. Ltd. | ANADA 200-815 | Approved | Jul 31, 2025 |
|
Cefpodoxime Proxetil Tablets
RX
Cefpodoxime proxetil
Tablet
• Oral
|
Dechra Veterinary Products LLC | ANADA 200-543 | Approved | Mar 16, 2019 |
|
Simplicef®
RX
Cefpodoxime proxetil
Tablet and Chewable Tablet
• Oral
|
Zoetis Inc. | NADA 141-232 | Approved | Mar 15, 2019 |
Data source: FDA Animal Drugs @ FDA (public search export).
What It's For (FDA Label Highlights)
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
Composition / specifications
For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius, S. aureus, Streptococcus canis (group G, beta-hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.
5 to 10 mg per kilogram (2.3 to 4.5 mg per pound) body weight daily for 5 to 7 days, or for 2 to 3 days beyond the cessation of clinical signs, up to a maximum of 28 days.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus canis (group G, ß hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis
FDA page: Open in Animal Drugs @ FDA
For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius, Staphylococcus aureus, Streptococcus canis (group G, ß hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.
5 to 10 milligram per kilogram (2.3 to 4.5 milligram per pound) body weight daily for 5 to 7 days, or for 2 to 3 days beyond the cessation of clinical signs, up to a maximum of 28 days.
FDA page: Open in Animal Drugs @ FDA
Official Documents (FDA)
Direct links to FDA-hosted PDFs and SPL packages (when available).
-
Summary
For the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of Staphylococcus pseudintermedius, Staphylococcus aureus, Streptococcus canis (group G, β hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.
FDA page: Open in Animal Drugs @ FDA
-
FOI UCM338192.pdf
Summary
For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus canis (group G, ß hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.
FDA page: Open in Animal Drugs @ FDA
-
FOI UCM433791.pdf
Summary
This supplement provides for the addition of a flavored, chewable tablet. -
FOI ucm118043.pdf
Summary
For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus canis (group G, ß hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.
- Simplicef® (ZIP)
FDA page: Open in Animal Drugs @ FDA
Usage
For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , Staphylococcus aureus , Streptococcus canis (group G, ß hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis . For the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of Staphylococcus intermedius , Staphylococcus aureus , Streptococcus canis (group G, ß hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , S. aureus , Streptococcus canis (group G, beta-hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis .
Source: FDA Animal Drugs @ FDA • Reference
Contraindications
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian
Side Effects
No approved side-effect narrative is linked yet.
openFDA reaction signals are available for Dog 56 and Cat 56 (view top reported reactions).
Top Reported Reactions (openFDA)
Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Adverse Event Case Summaries (openFDA)
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Dog, Terrier - Bull - American Pit, Male, 14 year, 24.494 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Stiff gait, Cognitive disorder NOS, Malaise, Vomiting, Diarrhea… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-055236
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 14.00 Year
- Weight: 24.494 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Unassigned
Dog, Mastiff (unspecified), Male, 5.5 year, 90.26 kilogram • Drug: MSK, Unknown • Reactions: Regenerative anaemia, Tiredness (lethargy), Localised oedema, Uncomfortable, Lack of efficacy - NOS… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-054417
- Serious AE: No
- Treated For AE: Yes
- Sex: Male
- Age: 5.50 Year
- Weight: 90.260 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
Dog, Terrier - Boston, Female, 13 year, 9.979 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Facial swelling (possible allergy), Head tilt - neurological disorder, Staggering • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-055030
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Female
- Age: 13.00 Year
- Weight: 9.979 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Unassigned
Dog, Terrier - Fox Wire, Male, 10.8 year, 9.68 kilogram • Drug: MSK, Oral, Dose: 100 Milligram per animal, Frequency: 24 per hour • Reactions: Deafness, Tympanic rupture, Application site discharge NOS • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-053873
- Serious AE: Yes
- Treated For AE: No
- Sex: Male
- Age: 10.80 Year
- Weight: 9.680 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Dose: 100 Milligram per animal
- Frequency: 24 per hour
Dog, Shepherd Dog - German, Male, 4.9 year, 35.11 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Lack of efficacy - NOS • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-055356
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 4.90 Year
- Weight: 35.110 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Unassigned
Cat, Domestic Shorthair, Male, 6 year, 5.443 kilogram • Drug: MSK, Oral • Reactions: Loss of appetite, Ketosis, Elevated alanine aminotransferase, Elevated blood urea nitrogen, Elevated serum alkaline phosphatase… • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-052288
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 6.00 Year
- Weight: 5.443 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
Cat, Domestic Mediumhair, Male, 14 year, 6.65 kilogram • Drug: MSK, Tablet, Oral, Dose: 50 Milligram per animal, Frequency: 1 per day • Reactions: Hair loss NOS, Joint swelling, Vocalisation, Joint pain, Abnormal radiograph finding… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-013835
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 14.00 Year
- Weight: 6.650 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
- Dose: 50 Milligram per animal
- Frequency: 1 per day
Cat, Domestic Shorthair, Female, 10 year, 6.976 kilogram • Drug: MSK, Oral • Reactions: Application site irritation, Application site hair loss • Outcome: Ongoing
- Report ID: USA-USFDACVM-2024-US-063739
- Serious AE: No
- Treated For AE: Yes
- Sex: Female
- Age: 10.00 Year
- Weight: 6.976 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Overdose Information
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
Storage & Handling
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Share Your Thoughts
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.